- Thursday, September 21, 2023
8:00 AM – 8:15 AM ET
Welcome
8:00 AM – 8:15 AM ET
WelcomeCo-Chair: – University of California, Los Angeles
Co-Chair: – Abramson Cancer Center, Hospital of the University of Pennsylvania
Edward B. Garon, MD, MS – University of California, Los Angeles ### 758743###Co-Chair###Professor###University of California, Los Angeles###Co-Chair: – University of California, Los Angeles
### @@@ Corey J. Langer, MD, FACP (he/him/his) – Abramson Cancer Center, Hospital of the University of Pennsylvania ### 758413###Co-Chair###Director of Thoracic Oncology ###Abramson Cancer Center, Hospital of the University of Pennsylvania###Co-Chair: – Abramson Cancer Center, Hospital of the University of Pennsylvania
### he/him/his8:15 AM – 9:00 AM ET
Session 1: Birdseye View of the Current Tretatment Landscape in Metastatic NSCLC without Actionable Mutations
8:15 AM – 9:00 AM ET
Session 1: Birdseye View of the Current Tretatment Landscape in Metastatic NSCLC without Actionable MutationsPresenter: – Cedars Sinai Medical Center
Karen Reckamp, MD – Cedars Sinai Medical Center ### 799344###Presenter###Professor###Cedars Sinai Medical Center###Presenter: – Cedars Sinai Medical Center
###
9:00 AM – 9:45 AM ET
Session 2: Sensitizing and Atypical EGFR Mutations
9:00 AM – 9:45 AM ET
Session 2: Sensitizing and Atypical EGFR MutationsPresenter: – Memorial Sloan Kettering Cancer Center
Gregory J. Riely, MD, PhD – Memorial Sloan Kettering Cancer Center ### 758419###Presenter###Member###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
###
9:45 AM – 9:50 AM ET
Exhibit Hall
9:45 AM – 9:50 AM ET
Break
9:50 AM – 10:50 AM ET
Non-CME Innovation Theater
9:50 AM – 10:50 AM ET
Non-CME Innovation Theater - Sponsored by AstraZeneca
10:50 AM – 11:00 AM ET
Exhibit Hall
10:50 AM – 11:00 AM ET
Exhibit Hall
11:00 AM – 11:45 AM ET
Session 3: EGFR: The Challenge of Primary and Secondary Resistance
11:00 AM – 11:45 AM ET
Session 3: EGFR: The Challenge of Primary and Secondary ResistancePresenter: – Memorial Sloan Kettering Cancer Center
Helena Yu, MD – Memorial Sloan Kettering Cancer Center ### 1345377###Presenter###Associate Attending###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
###
11:45 AM – 12:00 PM ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive
11:45 AM – 12:00 PM ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive - LorlatinibDebate Speaker: – University of California Irvine
Misako Nagasaka, MD, PhD – University of California Irvine ### 2123554###Debate Speaker###Associate Clinical Profssore###University of California Irvine###Debate Speaker: – University of California Irvine
###
12:00 PM – 12:15 PM ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive
12:00 PM – 12:15 PM ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive - AlectinibDebate Speaker: – Emory University
Ticiana Leal, MD (she/her/hers) – Emory University ### 1778151###Debate Speaker###Associate Professor, Thoracic Medical Oncology Program###Emory University###Debate Speaker: – Emory University
### she/her/hers
12:15 PM – 12:30 PM ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive
12:15 PM – 12:30 PM ET
Q&A PanelPanelist: – Emory University
Panelist: – University of California Irvine
Ticiana Leal, MD (she/her/hers) – Emory University ### 1778151###Panelist###Associate Professor, Thoracic Medical Oncology Program###Emory University###Panelist: – Emory University
### she/her/hers @@@ Misako Nagasaka, MD, PhD – University of California Irvine ### 2123554###Panelist###Associate Clinical Profssore###University of California Irvine###Panelist: – University of California Irvine
### 12:30 PM – 12:35 PM ET
Exhibit Hall
12:30 PM – 12:35 PM ET
Break
12:35 PM – 1:35 PM ET
Non-CME Innovation Theater
12:35 PM – 1:35 PM ET
Non-CME Innovation Theater - Sponsored by Sanofi
1:35 PM – 2:20 PM ET
Session 5: Special Topic – Unique Immune Combinations with CPIs
1:35 PM – 2:20 PM ET
Session 5: Unique Immune Combinations with CPIsPresenter: – Fox Chase Cancer Center
Hossein Borghaei, DO, MS – Fox Chase Cancer Center ### 2014938###Presenter###Professor and Chief, Thoracic Oncology###Fox Chase Cancer Center###Presenter: – Fox Chase Cancer Center
###
2:20 PM – 3:05 PM ET
Session 6: Advancing the Management of NSCLC: A Focus on Emerging Therapies
2:20 PM – 3:05 PM ET
Session 6: Advancing the Management of NSCLC: A Focus on Emerging TherapiesPresenter: – Emory University
Ticiana Leal, MD (she/her/hers) – Emory University ### 1778151###Presenter###Associate Professor, Thoracic Medical Oncology Program###Emory University###Presenter: – Emory University
### she/her/hers
3:05 PM – 3:35 PM ET
Exhibit Hall
3:05 PM – 3:35 PM ET
Exhibit Hall
3:35 PM – 4:20 PM ET
Session 7: The Era of ADCs in the Treatment of NSCLC Part 1: Class Overview and Specifics of TROP2, HER3, c-MET, and CEACAM5 Investigational ADCs
3:35 PM – 4:20 PM ET
Session 7: The Era of ADCs in the Treatment of NSCLC Part 1: Class Overview and Specifics of TROP2, HER3, c-MET, and CEACAM5 Investigational ADCs
Barbara Melosky, MD – Bc Cancer ### 1961092###Presenter###Medical Oncologist###Bc Cancer###Presenter: – Bc Cancer
###
4:20 PM – 5:05 PM ET
Session 8: HER2 and the Emerging Roles of HER Family ADCs
4:20 PM – 5:05 PM ET
Session 8: HER2 and the Emerging Roles of HER Family ADCsPresenter: – Rush University
Helen J. Ross, MD (she/her/hers) – Rush University ### 758420###Presenter###Thoracic Medical Oncologist, Director of Research and Clinical Trials###Rush University###Presenter: – Rush University
### she/her/hers
- Friday, September 22, 2023
8:00 AM – 8:15 AM ET
Welcome
8:00 AM – 8:15 AM ET
Welcome
8:15 AM – 9:00 AM ET
Session 9: The Primacy of Front-Line Checkpoint Inhibitors in NSCLC
8:15 AM – 9:00 AM ET
Session 9: The Primacy of Front-Line Checkpoint Inhibitors in NSCLCPresenter: – Princess Margaret Cancer Centre
Natasha Leighl, MD, FRCPC, FASCO – Princess Margaret Cancer Centre ### 1880423###Presenter###Lung Site Lead, Medical Oncology###Princess Margaret Cancer Centre###Presenter: – Princess Margaret Cancer Centre
### 9:00 AM – 9:07 AM ET
Session 10: Debate: How to Handle PD-L1 <1% - Chemo + IO
9:00 AM – 9:07 AM ET
Session 10: Debate: How to Handle PD-L1 <1% - Chemo + IODebate Speaker: – Cedars Sinai Medical Center
Karen Reckamp, MD – Cedars Sinai Medical Center ### 799344###Debate Speaker###Professor###Cedars Sinai Medical Center###Debate Speaker: – Cedars Sinai Medical Center
###
9:07 AM – 9:14 AM ET
Session 10: Debate: How to Handle PD-L1 <1% - IO Combos
9:07 AM – 9:14 AM ET
Session 10: Debate: How to Handle PD-L1 <1% - IO CombosDebate Speaker: – Fox Chase Cancer Center
Hossein Borghaei, DO, MS – Fox Chase Cancer Center ### 2014938###Debate Speaker###Professor and Chief, Thoracic Oncology###Fox Chase Cancer Center###Debate Speaker: – Fox Chase Cancer Center
###
9:14 AM – 9:21 AM ET
Session 10: Debate: How to Handle PD-L1 1-49% - Chemo + IO
9:14 AM – 9:21 AM ET
Session 10: Debate: How to Handle PD-L1 1-49% - Chemo + IODebate Speaker: – Cedars Sinai Medical Center
Karen Reckamp, MD – Cedars Sinai Medical Center ### 799344###Debate Speaker###Professor###Cedars Sinai Medical Center###Debate Speaker: – Cedars Sinai Medical Center
###
9:21 AM – 9:28 AM ET
Session 10: Debate: How to Handle PD-L1 1-49% - IO Only
9:21 AM – 9:28 AM ET
Session 10: Debate: How to Handle PD-L1 1-49% - IO OnlyDebate Speaker: – Fox Chase Cancer Center
Hossein Borghaei, DO, MS – Fox Chase Cancer Center ### 2014938###Debate Speaker###Professor and Chief, Thoracic Oncology###Fox Chase Cancer Center###Debate Speaker: – Fox Chase Cancer Center
###
9:28 AM – 9:45 AM ET
Session 10: Debates: How to Handle PD-L1
9:28 AM – 9:45 AM ET
Q&A PanelPanelist: – Fox Chase Cancer Center
Panelist: – Cedars Sinai Medical Center
Hossein Borghaei, DO, MS – Fox Chase Cancer Center ### 2014938###Panelist###Professor and Chief, Thoracic Oncology###Fox Chase Cancer Center###Panelist: – Fox Chase Cancer Center
### @@@ Karen Reckamp, MD – Cedars Sinai Medical Center ### 799344###Panelist###Professor###Cedars Sinai Medical Center###Panelist: – Cedars Sinai Medical Center
### 9:45 AM – 9:50 AM ET
Exhibit Hall
9:45 AM – 9:50 AM ET
Break
9:50 AM – 10:50 AM ET
Non-CME Innovation Theater
9:50 AM – 10:50 AM ET
Non-CME Innovation Theater - Sponsored by Catalyst
10:50 AM – 11:00 AM ET
Exhibit Hall
10:50 AM – 11:00 AM ET
Exhibit Hall
11:00 AM – 11:45 AM ET
Session 11: Fusions as a Target in Lung Cancer: RET, NTRK, NRG1, ROS1
11:00 AM – 11:45 AM ET
Session 11: Fusions as a Target in Lung Cancer: RET, NTRK, NRG1, ROS1Presenter: – Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Deborah Doroshow, MD, PhD – Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai ### 1941811###Presenter###Assistant Professor###Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai###Presenter: – Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
###
11:45 AM – 12:30 PM ET
Session 12: Updates from Recent Meetings
11:45 AM – 12:30 PM ET
Session 12: Updates from Recent MeetingsPresenter: – Rush University
Helen J. Ross, MD (she/her/hers) – Rush University ### 758420###Presenter###Thoracic Medical Oncologist, Director of Research and Clinical Trials###Rush University###Presenter: – Rush University
### she/her/hers
12:30 PM – 1:35 PM ET
Lunch Break
12:30 PM – 1:35 PM ET
Lunch Break
1:35 PM – 1:42 PM ET
Debate: How to Handle PD-L1 >50% - Chemo + IO
1:35 PM – 1:42 PM ET
Session 13: Debate: How to Handle PD-L1 >50% - Chemo + IOPresenter: – Johns Hopkins University
Patrick Forde, MD – Johns Hopkins University ### 1765848###Presenter###Co-Director, Division of Upper Aerodigestive Malignancies###Johns Hopkins University###Presenter: – Johns Hopkins University
###
1:42 PM – 1:49 PM ET
Debate: How to Handle PD-L1 >50% - IO Only
1:42 PM – 1:49 PM ET
Session 13: Debate: How to Handle PD-L1 >50% - IO OnlyPresenter: – Memorial Sloan Kettering Cancer Center
Jamie E. Chaft, MD – Memorial Sloan Kettering Cancer Center ### 758405###Presenter###Associate Attending Physician###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
###
1:49 PM – 1:56 PM ET
Debate: Neoadjuvant vs Adjuvant Therapy - Neoadjuvant
1:49 PM – 1:56 PM ET
Session 13: Debate: Neoadjuvant vs Adjuvant Therapy - NeoadjuvantPresenter: – Memorial Sloan Kettering Cancer Center
Jamie E. Chaft, MD – Memorial Sloan Kettering Cancer Center ### 758405###Presenter###Associate Attending Physician###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
###
1:56 PM – 2:03 PM ET
Debate: Neoadjuvant vs Adjuvant Therapy - Adjuvant
1:56 PM – 2:03 PM ET
Session 13: Debate: Neoadjuvant vs Adjuvant Therapy - AdjuvantPresenter: – Johns Hopkins University
Patrick Forde, MD – Johns Hopkins University ### 1765848###Presenter###Co-Director, Division of Upper Aerodigestive Malignancies###Johns Hopkins University###Presenter: – Johns Hopkins University
###
2:03 PM – 2:20 PM ET
Session 13: Debates: How to Handle PD-L1 and Neoadjuvant vs Adjuvant
2:03 PM – 2:20 PM ET
Q&A PanelPanelist: – Johns Hopkins University
Panelist: – Memorial Sloan Kettering Cancer Center
Patrick Forde, MD – Johns Hopkins University ### 1765848###Panelist###Co-Director, Division of Upper Aerodigestive Malignancies###Johns Hopkins University###Panelist: – Johns Hopkins University
### @@@ Jamie E. Chaft, MD – Memorial Sloan Kettering Cancer Center ### 758405###Panelist###Associate Attending Physician###Memorial Sloan Kettering Cancer Center###Panelist: – Memorial Sloan Kettering Cancer Center
### 2:20 PM – 3:05 PM ET
Session 14: Targeted Therapy for MET-Dependent Lung Cancers: Have We Met Our Match?
2:20 PM – 3:05 PM ET
Session 14: Targeted Therapy for MET-Dependent Lung Cancers: Have We Met Our Match?Presenter: – Princess Margaret Cancer Centre
Natasha Leighl, MD, FRCPC, FASCO – Princess Margaret Cancer Centre ### 1880423###Presenter###Lung Site Lead, Medical Oncology###Princess Margaret Cancer Centre###Presenter: – Princess Margaret Cancer Centre
### 3:05 PM – 3:35 PM ET
Exhibit Hall
3:05 PM – 3:35 PM ET
Exhibit Hall
3:35 PM – 4:20 PM ET
Session 15: KRAS Mutations: Taming a "Defiant" Oncogene in NSCLC
3:35 PM – 4:20 PM ET
Session 15: KRAS Mutations: Taming a "Defiant" Oncogene in NSCLCPresenter: – NYU Langone Health Perlmutter Cancer Center
Joshua K. Sabari, MD – NYU Langone Health Perlmutter Cancer Center ### 1759644###Presenter###Assistant Professor of Medicine###NYU Langone Health Perlmutter Cancer Center###Presenter: – NYU Langone Health Perlmutter Cancer Center
###
4:20 PM – 5:05 PM ET
Session 16: BRAF Mutations: Identifying and Addressing a Rare Oncogenic Driver
4:20 PM – 5:05 PM ET
Session 16: BRAF Mutations: Identifying and Addressing a Rare Oncogenic DriverPresenter: – University of California, San Diego
Lyudmila Bazhenova, MD – University of California, San Diego ### 1612022###Presenter###Professor of Medicine###University of California, San Diego###Presenter: – University of California, San Diego
###
- Saturday, September 23, 2023
8:00 AM – 8:15 AM ET
Welcome
8:00 AM – 8:15 AM ET
WelcomeCo-Chair: – University of California, Los Angeles
Edward B. Garon, MD, MS – University of California, Los Angeles ### 758743###Co-Chair###Professor###University of California, Los Angeles###Co-Chair: – University of California, Los Angeles
### 8:15 AM – 9:00 AM ET
Session 17: The Road from DNA to Protein: Navigating the Minefield of Expression Amplification and Mutation
8:15 AM – 9:00 AM ET
Session 17: The Road from DNA to Protein: Navigating the Minefield of Expression Amplification and MutationPresenter: – The University of Texas MD Anderson Cancer Center
Ignacio Wistuba, MD (he/him/his) – The University of Texas MD Anderson Cancer Center ### 1947025###Presenter###Professor and Chair###The University of Texas MD Anderson Cancer Center###Presenter: – The University of Texas MD Anderson Cancer Center
### he/him/his
9:00 AM – 9:45 AM ET
Session 18: The Power of Patient Advocacy
9:00 AM – 9:45 AM ET
Session 18: The Power of Patient AdvocacyPresenter: – Lung Cancer Foundation of America
Kim Norris – Lung Cancer Foundation of America ### 1947019###Presenter###President###Lung Cancer Foundation of America###Presenter: – Lung Cancer Foundation of America
###
9:45 AM – 10:05 AM ET
Break
9:45 AM – 10:05 AM ET
Break
10:05 AM – 10:50 AM ET
Session 19: Serial Monitoring Using Liquid Biopsy
10:05 AM – 10:50 AM ET
Session 19: Serial Monitoring Using Liquid Biopsy
Christian Rolfo, MD – Mount Sinai ### 1878455###Presenter###Professor and Assoc. Director for Clinical Research###Mount Sinai###Presenter: – Mount Sinai
###
10:50 AM – 11:35 AM ET
Session 20: Understanding Lambert-Eaton Myasthenic Syndrome and Its Association with Small Cell Lung Cancer
10:50 AM – 11:35 AM ET
Session 20: Understanding Lambert-Eaton Myasthenic Syndrome and Its Association with Small Cell Lung CancerPresenter: – Emory University Winship Cancer Institute
Jennifer Carlisle, MD (she/her/hers) – Emory University Winship Cancer Institute ### 2014901###Presenter###Assistant Professor###Emory University Winship Cancer Institute###Presenter: – Emory University Winship Cancer Institute
### she/her/hers
11:35 AM – 12:20 PM ET
Lunch Break
11:35 AM – 12:20 PM ET
Lunch Break
12:20 PM – 1:05 PM ET
Session 21: Finally Moving Forward in SCLC: The Pace of Progress is No Longer Glacial
12:20 PM – 1:05 PM ET
Session 21: Finally Moving Forward in SCLC: The Pace of Progress is No Longer GlacialPresenter: – Memorial Sloan Kettering Cancer Center
Charles Rudin, MD, PhD – Memorial Sloan Kettering Cancer Center ### 1765861###Presenter###Deputy Director###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
###
1:05 PM – 1:15 PM ET
Exhibit Hall
1:05 PM – 1:15 PM ET
Exhibit Hall
1:15 PM – 1:30 PM ET
Session 22: Debate: Prophylactic Cranial Irradiation (PCI) in SCLC - Yes
1:15 PM – 1:30 PM ET
Session 22: Debate: Prophylactic Cranial Irradiation (PCI) in SCLC - YesPresenter: – Memorial Sloan Kettering Cancer Center and New York Proton Center
Charles Simone, MD – Memorial Sloan Kettering Cancer Center and New York Proton Center ### 1878456###Presenter###Professor and Chief Medical Officer###Memorial Sloan Kettering Cancer Center and New York Proton Center###Presenter: – Memorial Sloan Kettering Cancer Center and New York Proton Center
###
1:30 PM – 1:45 PM ET
Session 22: Debate: Prophylactic Cranial Irradiation (PCI) in SCLC - No
1:30 PM – 1:45 PM ET
Session 22: Debate: Prophylactic Cranial Irradiation (PCI) in SCLC - NoPresenter: – Memorial Sloan Kettering Cancer Center
Daniel Gomez, MD – Memorial Sloan Kettering Cancer Center ### 1883757###Presenter###Director of Thoracic Radiation Oncology###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
###
1:45 PM – 2:00 PM ET
Session 22: Debate: Prophylactic Cranial Irradiation (PCI) in SCLC
1:45 PM – 2:00 PM ET
Q&A PanelPanelist: – Memorial Sloan Kettering Cancer Center
Panelist: – Memorial Sloan Kettering Cancer Center and New York Proton Center
Daniel Gomez, MD – Memorial Sloan Kettering Cancer Center ### 1883757###Panelist###Director of Thoracic Radiation Oncology###Memorial Sloan Kettering Cancer Center###Panelist: – Memorial Sloan Kettering Cancer Center
### @@@ Charles Simone, MD – Memorial Sloan Kettering Cancer Center and New York Proton Center ### 1878456###Panelist###Professor and Chief Medical Officer###Memorial Sloan Kettering Cancer Center and New York Proton Center###Panelist: – Memorial Sloan Kettering Cancer Center and New York Proton Center
### 2:00 PM – 2:45 PM ET
Session 23: How to Handle PS2 Patients and the Elderly
2:00 PM – 2:45 PM ET
Session 23: How to Handle PS2 Patients and the ElderlyPresenter: – Abramson Cancer Center, Hospital of the University of Pennsylvania
Corey J. Langer, MD, FACP (he/him/his) – Abramson Cancer Center, Hospital of the University of Pennsylvania ### 758413###Presenter###Director of Thoracic Oncology ###Abramson Cancer Center, Hospital of the University of Pennsylvania###Presenter: – Abramson Cancer Center, Hospital of the University of Pennsylvania
### he/him/his
